Development of an adjuvant active nonionic block copolymer for use in oil-free subunit vaccines formulations

被引:30
作者
Todd, CW
Pozzi, LAM
Guarnaccia, JR
Balasubramanian, M
Henk, WG
Younger, LE
Newman, MJ
机构
[1] CYTRX CORP,NORCROSS,GA 30092
[2] LOUISIANA STATE UNIV,SCH VET MED,VAN,BATON ROUGE,LA 70803
关键词
adjuvant; copolymer; CRL1995; vaccine;
D O I
10.1016/S0264-410X(97)00209-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Nonionic block copolymers, synthesized from repeating units of oxypropylene and oxyethylene, can be designed so that individual copolymers have unique physical properties with differential levels of adjuvant activity. We have designed high molecular weight block copolymers that spontaneously assemble into 500 nm-3 mu m particles when formulated with protein antigens in aqueous solutions at physiological pH. The adjuvant activity of one of these copolymers, termed CRL1005, was compared to selected research adjuvants using ovalbumin (OVA) as the prototype vaccine antigen. Suboptimal doses of OVA were formulated with complete and incomplete Freund's adjuvant (CFA/IFA), alum, Quil-A saponins, Ribi Adjuvant System (RAS) or the CRL1005 copolymer and these formulations were used to immunize C57BL/6 mice. The CRL1005 copolymer appeared to be more potent than either Quil-A or alum and comparable to the RAS formulation, based on the numbers of responding mice and the OVA-specific antibody titers. Alum, RAS and Quil-A all augmented the production of IgG(1) and IgG(2b) similarly whereas only the CFA/IFA boosted IgG(2a) levels significantly. The effect of adjuvants on relative antibody affinity was more variable with the CRL1005 and CFA/IFA inducing antibodies with the highest affinity scores. This high molecular weight nonionic copolymer is nontoxic in aqueous formulations and should therefore be compatible with a wide variety of protein or polysaccharide vaccine antigens. (C) 1997 Published by Elsevier Science Ltd.
引用
收藏
页码:564 / 570
页数:7
相关论文
共 47 条
  • [1] ALFONSO LCC, 1994, SCIENCE, V263, P235
  • [2] LIPOSOMES AS IMMUNOLOGICAL ADJUVANTS
    ALLISON, AC
    GREGORIADIS, G
    [J]. NATURE, 1974, 252 (5480) : 252 - 252
  • [3] LIPOPOLYSACCHARIDE, LIPID-A, AND LIPOSOMES CONTAINING LIPID-A AS IMMUNOLOGICAL ADJUVANTS
    ALVING, CR
    [J]. IMMUNOBIOLOGY, 1993, 187 (3-5) : 430 - 446
  • [4] AREND WP, 1986, CLIN EXP IMMUNOL, V64, P656
  • [5] DISTINCTIVE ADJUVANTICITY OF SYNTHETIC ANALOGS OF MYCOBACTERIAL WATER-SOLUBLE COMPONENTS
    AUDIBERT, F
    CHEDID, L
    LEFRANCIER, P
    CHOAY, J
    [J]. CELLULAR IMMUNOLOGY, 1976, 21 (02) : 243 - 249
  • [6] Chernoff D, 1995, VACCINE DESIGN SUBUN, P277
  • [7] CLELAND JL, 1995, VACCINE DESIGN SUBUN, P439
  • [8] INVITRO SPLEEN-CELL RESPONSIVENESS TO VARIOUS ANALOGS OF MDP (N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE), A SYNTHETIC IMMUNOADJUVANT, IN MDP HIGH-RESPONDER MICE
    DAMAIS, C
    PARANT, M
    CHEDID, L
    LEFRANCIER, P
    CHOAY, J
    [J]. CELLULAR IMMUNOLOGY, 1978, 35 (01) : 173 - 179
  • [9] BIODEGRADABLE MICROSPHERES AS A VACCINE DELIVERY SYSTEM
    ELDRIDGE, JH
    STAAS, JK
    MEULBROEK, JA
    MCGHEE, JR
    TICE, TR
    GILLEY, RM
    [J]. MOLECULAR IMMUNOLOGY, 1991, 28 (03) : 287 - 294
  • [10] IMMUNOPOTENTIATING EFFECTS OF THE ADJUVANTS SGP AND QUIL-A .1. ANTIBODY-RESPONSES TO T-DEPENDENT AND T-INDEPENDENT ANTIGENS
    FLEBBE, LM
    BRALEYMULLEN, H
    [J]. CELLULAR IMMUNOLOGY, 1986, 99 (01) : 119 - 127